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1Hydro-electrolyte disturbances are frequent in post–myo-cardial infarction (MI) with or without associated heart 
failure (HF). Water and electrolyte disorders are often associ-
ated with dismal prognosis despite prompt correction.1,2
See Clinical Perspective
In particular, the occurrence of hyponatremia in MI and HF 
settings is a well-established, strong, and independent pre-
dictor of short- and long-term morbidity and mortality.3–7 On 
the contrary, despite being broadly available in routine blood 
chemistry panels and its involvement in contraction alkalosis 
during excessive decongestion therapy, the anion chloride has 
not received the same attention as its sodium counterpart.8
Recently published studies have analyzed independent 
cohorts of acute and chronic HF.9–12 In these samples, serum 
chloride levels were found to be independently and inversely 
associated with mortality after multivariable adjustment for sev-
eral well-established prognostic factors including serum sodium 
concentration. Whether this may also apply to high-risk MI (ie, 
MI complicated by left ventricular systolic dysfunction and HF) 
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Background—Serum chloride levels were recently found to be independently associated with mortality in heart failure (HF).
Methods and Results—We investigated the relationship between serum chloride and clinical outcomes in 7195 subjects with 
acute myocardial infarction complicated by reduced left ventricular function and HF. The studied outcomes were all-cause 
mortality, cardiovascular mortality, and hospitalization for HF. Both chloride and sodium had a nonlinear association 
with the studied outcomes (P<0.05 for linearity). Patients in the lowest chloride tertile (chloride ≤100) were older, had 
more comorbidities, and had lower sodium levels (P<0.05 for all). Serum chloride showed a significant interaction with 
sodium with regard to all studied outcomes (P for interaction <0.05 for all). The lowest chloride tertile (≤100 mmol/L) 
was associated with increased mortality rates in the context of lower sodium (≤138 mmol/L; adjusted hazard ratio [95% 
confidence interval] for all-cause mortality=1.42 (1.14–1.77); P=0.002), whereas in the context of higher sodium levels 
(>141 mmol/L), the association with mortality was lost. Spline-transformed chloride and its interaction with sodium did 
not add significant prognostic information on top of other well-established prognostic variables (P>0.05 for all outcomes).
Conclusions—In post–myocardial infarction with systolic dysfunction and HF, low serum chloride was associated with 
mortality (but not hospitalization for HF) in the setting of lower sodium. Overall, chloride and its interaction with sodium 
did not add clinically relevant prognostic information on top of other well-established prognostic variables. Taken 
together, these data support an integrated and critical consideration of chloride and sodium interplay.  
(Circ Heart Fail. 2017;10:e003500. DOI: 10.1161/CIRCHEARTFAILURE.116.003500.)
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populations is yet to be determined. Moreover, these variables 
may be likely to have a nonlinear association with outcomes; 
hence, linearity should be tested to perform informative analysis.
In light of the above, our aims were (1) to study the shape 
of the association between chloride, sodium, and the studied 
outcomes; (2) to evaluate the prognostic value and indepen-
dency of chloride levels in high-risk MI populations; (3) to 
study the correlation and interplay between serum chloride 
and sodium; and (4) to assess the prognostic information gain 
provided by serum chloride levels on top of sodium.
Methods
Study Sample: The High-Risk MI Database 
Initiative
For this study, we used a previously published cohort of pooled pa-
tient data.13 In the present analysis, data from the EPHESUS14,15 
trial (Eplerenone, a Selective Aldosterone Blocker, in Patients With 
Left Ventricular Dysfunction After Myocardial Infarction) and the 
CAPRICORN16,17 randomized trial (Effect of Carvedilol on Outcome 
After Myocardial Infarction in Patients With Left-Ventricular 
Dysfunction) were used in which serum chloride levels were avail-
able (measured at randomization from 12 hours to 21 days after MI). 
Full details of total enrolled patients, the inclusion and exclusion cri-
teria for each trial, the end points, and the results have been published 
previously.13 Each trial enrolled patients with left ventricular systolic 
dysfunction and HF between 12 hours and 21 days after acute MI. HF 
was defined by the presence of pulmonary rales, chest radiography 
showing pulmonary congestion, or the presence of a third heart sound.
A total of 7195 patients with available chloride values were in-
cluded: 5959 patients included from the EPHESUS trial and 1236 
from the CAPRICORN trial. The pooled data were used to increase 
the power and precision of the associations. There were no significant 
differences (ie, interactions) in the prognostic value of chloride (and 
sodium) between these studies (P value for interaction >0.1 for all 
outcomes), thereby avoiding the introduction of heterogeneity to the 
results. The characteristics of the patients included and excluded from 
the analysis are shown in Table I in the Data Supplement, and the 
interaction tests between the analyzed studies are provided in Table II 
in the Data Supplement.
The respective chairpersons of the Steering Committees of the 4 
trials initiated the pooling project.
The study was conducted in accordance with the Declaration of 
Helsinki and approved by site ethics committees. All participants 
gave written informed consent to participate in the trials.
Chloride Determination
Data from routine laboratory testing at a central core laboratory 
for each trial were collected in all patients enrolled in these trials. 
Laboratory measurements were obtained at the time of randomization.
Outcomes
The present study analyzed all-cause mortality (ACM), cardiovascu-
lar mortality (CVM), and hospitalization for HF (HHF) as outcomes. 
These outcomes were independently adjudicated and recorded within 
each trial.
Statistical Methods
In descriptive analyses, continuous variables are expressed as 
mean±SD if normally distributed or as median (percentile25–75) if 
skewed. Ordinal variables are expressed as frequencies and propor-
tions (%). Missing values were excluded from the analysis.
The linearity assumption of the relationship between chloride and 
the log-hazard of outcome was assessed using restricted cubic splines 
with 3 knots located to the 10th, 50th, and 90th percentiles accord-
ing to the Harrell rule (respectively 96, 102, and 108 mmol/L). This 
generates 2 components: one linear and the other nonlinear. If the 
Wald test associated with the nonlinear component was statistically 
significant, a nonlinear relationship was assumed (P value for linear-
ity <0.01 for ACM and CVM and P=0.092 for HHF; Table III in the 
Data Supplement).
Univariable time-to-event comparisons were performed using the 
log-rank test, and survival was estimated with the Kaplan–Meier meth-
od for ordinal dependent variables. Cox proportional hazard regression 
models were used to model long-term survival as a function of the 
formulas both in univariable and multivariable analysis. Proportional 
hazards assumptions for dependent variables were visually assessed by 
plotting the log(−log(S(t))) function as a function of survival time (t), 
where S(t) represents the survival function. An interaction term between 
the variable of interest and time was tested within the Cox model. In the 
multivariable models, the covariates were chosen from demographic 
(age and sex), clinical (systolic blood pressure, history of diabetes mel-
litus, body mass index, atrial fibrillation, Killip class, left ventricular 
ejection fraction, diuretic use, and HF history), and laboratory vari-
ables (hemoglobin, plasma blood urea nitrogen levels, and estimated 
glomerular filtration rate calculated by the chronic kidney disease- epi-
demiology collaboration equation18) that were previously found to be 
clinically relevant.19 The interaction between chloride*sodium with 
each outcome was systematically tested using cubic spline variable 
transformation and categories. Subsequent subgroup analyses were 
performed to clearly interpret the effect modification.
The relative importance and the discriminative capacity of chloride 
on top of a prognostic model including the aforementioned covariates 
and sodium*chloride interaction with regard to the studied outcomes 
was evaluated by the Harrell c-index20 and compared with the corre-
lated c-indices using the approach proposed by Kang et al.21 The value 
of serum chloride for prediction improvement on top of the same ad-
justment model and sodium*chloride interaction was performed with 
the net reclassification improvement (NRI) method and assessed at the 
median follow-up time for each outcome.22,23 This method assesses the 
ability of a new model to reclassify subjects with and without a clinical 
event during follow-up. The ability of the new model to reclassify is 
summarized by the NRI statistic. The continuous NRI method devel-
oped by Uno et al23 and implemented in the survIDINRI package of the 
R software (The R Foundation for Statistical Computing) was used. 
The continuous NRI method does not require a previous definition of 
strata risk, thus considering the change in the estimation prediction as a 
continuous variable. The integrated discrimination improvement (IDI) 
was also calculated. It evaluates the difference between the integrated 
sensitivity gain and the integrated specificity loss because of the addi-
tion of the chloride estimator to the prognostic model.
Statistical analyses were performed using SPSS 23 software 
(Released 2013; IBM SPSS Statistics for Windows, version 23.0; IBM 
Corporation, Armonk, NY) and the R software (The R Foundation for 
Statistical Computing).
A P value <0.05 was considered statistically significant, except 
for interaction and linearity tests where a P value <0.1 was considered 
significant.24
Results
Baseline (ie, Randomization) Characteristics of the 
Study Sample
A total of 7195 patients were included in the study. Patients 
in the lowest chloride tertile (chloride ≤100) were older, were 
more often diabetic, and had a higher prevalence of atrial 
fibrillation, previous MI, HF history, and peripheral artery dis-
ease. They also were more frequently in Killip class III/IV and 
had a lower systolic blood pressure, higher heart rate, worse 
renal function, lower sodium level, and lower mean left ven-
tricular ejection fraction. They were more frequently receiv-
ing diuretics and digoxin (P<0.05 for all; Table 1). Patients 
in the lowest sodium tertile (sodium ≤138) also had higher 
heart rate and lower systolic blood pressure, left ventricular 
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ejection fraction, and chloride levels but did not present the 
other characteristics associated with lower chloride (ie, age, 
diabetes mellitus, atrial fibrillation, HF history, previous MI, 
and peripheral artery disease), and Killip class were not sig-
nificantly different between sodium subgroups (Table IV in 
the Data Supplement).
The median (percentile25–75) follow-up time was 485 days 
(352–631 days) for ACM and CMV and 456 days (302–612 
days) for HHF. The end point ACM occurred in 1084 patients 
(15%), CVM in 937 patients (13%), and HHF in 948 patients 
(13%) during the follow-up.
Chloride and Sodium Correlation
Pearson correlation between serum chloride and sodium was 
0.413 (P<0.001) meaning that these variables potentially 
incorporate distinct information.
Table 1. Baseline Characteristics of the Study Sample
 Baseline Chloride, mmol/L  
Variable Total ≤100 >100 to ≤104 >104 P Value for Trend % MV
Demographic
  Patients, n (%) 7195 2525 (35.1) 2555 (35.5) 2115 (29.4) … 0
  Age, y 63.6±11.6 64.0±11.6 63.1±11.6 63.8±11.4 0.008 0
  Male sex, n (%) 5183 (72) 1780 (71) 1877 (74) 1526 (72) 0.069 0
Clinical
Hypertension, n (%) 4180 (58) 1498 (59) 1469 (58) 1213 (57) 0.27 0
Diabetes mellitus, n (%) 2254 (31) 932 (37) 788 (31) 534 (25) <0.001 0
Atrial fibrillation, n (%) 891 (12) 371 (15) 294 (12) 226 (11) <0.001 0
Previous MI, n (%) 1978 (28) 747 (30) 662 (26) 569 (27) 0.010 0
HF history, n (%) 1392 (19) 531 (21) 458 (18) 403 (19) 0.017 0
PAD, n (%) 834 (12) 307 (12) 284 (11) 244 (12) 0.50 0
SBP, mm Hg 119.1±16.6 118.5±16.8 119.0±16.6 120.0±16.2 0.011 0.2
Heart rate, beats per min 75.3±11.9 76.6±12.1 75.0±11.7 74.0±11.7 <0.001 0.3
BMI, kg/m2 27.4±4.5 27.2±5.0 27.6±4.5 27.4±4.4 0.035 0.9
Killip III/IV, n (%) 1221 (17) 503 (20) 373 (15) 345 (16) <0.001 0.6
Laboratory
Serum Cr, mg/dL 1.14±0.32 1.16±0.34 1.14±0.31 1.12±0.32 0.010 0.1
eGFR, mL/min/1.73 m2 67.8±20.6 66.6±20.8 68.5±20.3 68.3±20.7 0.001 0.1
Serum BUN, mg/dL 26.8±16.0 27.9±17.0 25.7±15.3 26.7±15.5 <0.001 1.7
Serum sodium, mmol/L 139.3±4.1 137.4±4.3 139.4±3.4 141.5±3.6 0.001 0.1
  ≤138 2928 (41) 1545 (61) 994 (39) 388 (18) <0.001
  >138 to ≤141 2277 (32) 615 (24) 949 (37) 714 (34) <0.001
  >141 1985 (28) 361 (14) 610 (24) 1014 (48) <0.001
Serum potassium, mmol/L 4.3±0.5 4.3±0.5 4.3±0.4 4.4±0.4 <0.001 0.4
Hemoglobin, g/dL 13.3±1.7 13.4±1.7 13.4±1.7 13.2±1.7 0.003 1.0
Echocardiographic
  LVEF, % 33.0±6.2 32.6±6.3 33.1±6.2 33.5±5.9 <0.001 0.3
  LVEF ≤35%, n (%) 4319 (60) 1564 (62) 1555 (61) 1200 (57) 0.001 …
Medications
  ACEi/ARB, n (%) 5991 (83) 2111 (84) 2148 (84) 1732 (82) 0.12 0.1
  β-blocker, n (%) 4132 (69) 1434 (67) 1456 (72) 1242 (69) <0.001 17.2
  Digoxin, n (%) 919 (13) 393 (16) 302 (12) 224 (11) <0.001 0.1
  Diuretics, n (%) 3703 (52) 1509 (60) 1237 (48) 957 (45) <0.001 0.1
Results expressed as mean±SD if the distribution is normal; median (percentile25–75) if the distribution is skewed; and number (n) and proportions (%) if ordinal. ACEi 
indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; Cr, creatinine; eGFR, estimated 
glomerular filtration rate by chronic kidney disease–epidemiology collaboration formula and expressed in mL/min/1.73 m2; HF, heart failure; LVEF, left ventricular 
ejection fraction; MI, myocardial infarction; MV, missing values; PAD, peripheral artery disease; and SBP, systolic blood pressure.
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Survival Analysis
Serum chloride had a nonlinear association with all studied out-
comes (Figure 1). A significant interaction was found between 
chloride and sodium regarding the 3 studied outcomes, both 
as continuous splines (ACM P for interaction=0.023; CVM P 
for interaction=0.019; and HHF P for interaction=0.002) and 
ordinal variables (ACM P for interaction=0.027; CVM P for 
interaction=0.028; and HHF P for interaction <0.001; Table 2).
Serum chloride as a continuous cubic spline variable was 
only independently associated with ACM and CVM in the 
lower serum sodium tertile (ie, sodium <138 mmol/L). The 
chloride cutoff point below which these associations became 
significant was ≈97 mmol/L. For the other sodium categories 
(ie, 139–141 and >141 mmol/L), the associations were not 
significant. Although low chloride concentrations were asso-
ciated with increased mortality in the context of lower sodium, 
high serum chloride was also likely to be associated with an 
increase in ACM and CVM in this setting because the asso-
ciation was U shaped; however, the associations for higher 
chloride were less precise and statistically nonsignificant 
(Figure 1). Low serum chloride was not significantly associ-
ated with increased HHF in the lower serum sodium tertile. 
However, in the higher serum sodium tertile (ie, sodium >141 
mmol/L), low serum chloride (ie, <102 mmol/L) was associ-
ated with reduced HHF events, although only 19 events were 
observed in this subgroup along with (broad, wide) confidence 
intervals (CIs; Figure 1).
A lower serum chloride tertile (ie, <100 mmol/L) was asso-
ciated with increased ACM, CVM, and HHF in the context of 
the lower sodium category (ie, <138 mmol/L; adjusted hazard 
ratio [HR] [95% CI]=1.42 [1.14–1.77]; P=0.002 for ACM, 
adjusted HR [95% CI]=1.40 [1.11–1.77]; P=0.005 for CVM, 
and adjusted HR [95% CI]=1.34 [1.07–1.67]; P=0.009 for 
HHF). Statistically significant associations regarding ACM and 
CVM for the lower chloride tertile were also observed in the 
context of midrange sodium levels (ie, >138 to ≤141 mmol/L; 
adjusted HR [95% CI]=1.35 [1.03–1.78]; P=0.03 for ACM and 
adjusted HR [95% CI]=1.40 [1.11–1.77]; P=0.005 for CVM), 
whereas the associations for lower chloride in the context of 
midrange sodium regarding HHF were not significant (adjusted 
HR [95% CI]=1.07 [0.79–1.46]; P=0.65; Table 2). Of note, and 
as also evidenced by the continuous spline analysis, lower serum 
chloride tertile (ie, <100 mmol/L) was associated with reduced 
HHF events in the context of higher serum sodium (ie, >141 
mmol/L; HR [95% CI]=0.42 [0.25–0.69]; P=0.001; Table 2).
As observed in the univariable Kaplan–Meier curves in 
Figure 2, the cumulative survival (for ACM and CVM) was 
poorer in the lower chloride tertile only within the lower 
sodium tertiles, with the notable exception of HHF (ie, lower 
chloride tertile was also significantly associated with lower 
HHF rates within the higher sodium tertile).
On the contrary, after adjustment for potential confound-
ers, lower serum sodium was not associated with outcomes 
(except for HHF; Table V in the Data Supplement).
Figure 1. Relationship between serum chloride and all-cause mortality (ACM), cardiovascular mortality (CVM), and hospitalization for 
heart failure (HHF) within sodium tertiles. Red line, fitted curve; blue lines, 95% confidence interval (CI). Models adjusted for sex, age,  
systolic blood pressure, diabetes mellitus, atrial fibrillation, heart failure history, peripheral artery disease, hemoglobin, estimated glomeru-
lar filtration rate, blood urea nitrogen, left ventricular ejection fraction, Killip class, diuretic use, and body mass index. HR indicates  
hazard ratio.
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Table 2. Analysis of Sodium×Chloride Interaction for ACM, CVM, and HHF
  Crude HR (95% CI) P Value Adjusted HR (95% CI)* P Value
ACM Overall     
  Chloride ≤100 mmol/L 1.48 (1.28–1.71) <0.0001 1.29 (1.11–1.51) 0.0008
  Chloride >100 to ≤104 mmol/L Reference  Reference  
  Chloride >104 mmol/L 1.17 (0.99–1.37) 0.062 1.16 (0.98–1.37) 0.091
Sodium ≤138 mmol/L     
  Chloride ≤100 mmol/L 1.69 (1.37–2.08) <0.0001 1.42 (1.14–1.77) 0.002
  Chloride >100 to ≤104 mmol/L Reference  Reference  
  Chloride >104 mmol/L 1.33 (0.98–1.80) 0.066 1.32 (0.96–1.81) 0.085
Sodium >138 to ≤141 mmol/L     
  Chloride ≤100 mmol/L 1.62 (1.24–2.12) 0.0004 1.35 (1.03–1.78) 0.030
  Chloride >100 to ≤104 mmol/L Reference  Reference  
  Chloride >104 mmol/L 1.31 (1.00–1.72) 0.051 1.30 (0.99–1.72) 0.061
Sodium >141 mmol/L     
  Chloride ≤100 mmol/L 0.91 (0.64–1.29) 0.60 0.97 (0.68–1.39) 0.88
  Chloride >100 to ≤104 mmol/L Reference  Reference  
  Chloride >104 mmol/L 0.86 (0.66–1.13) 0.27 0.89 (0.68–1.17) 0.41
Interaction sodium tertiles×chloride tertiles  0.027  0.22
Interaction sodium tertiles×chloride splines  0.023  0.055
CVM Overall     
  Chloride ≤100 mmol/L 1.48 (1.27–1.73) <0.0001 1.29 (1.09–1.51) 0.002
  Chloride >100 to ≤104 mmol/L Reference  Reference  
  Chloride >104 mmol/L 1.14 (0.95–1.36) 0.15 1.12 (0.94–1.35) 0.20
Sodium ≤138 mmol/L     
  Chloride ≤100 mmol/L 1.66 (1.33–2.08) <0.0001 1.40 (1.11–1.77) 0.005
  Chloride >100 to ≤104 mmol/L Reference  Reference  
  Chloride >104 mmol/L 1.23 (0.88–1.72) 0.22 1.21 (0.86–1.72) 0.28
Sodium >138 to ≤141 mmol/L     
  Chloride ≤100 mmol/L 1.68 (1.26–2.24) 0.0004 1.40 (1.05–1.88) 0.023
  Chloride >100 to ≤104 mmol/L Reference  Reference  
  Chloride >104 mmol/L 1.35 (1.01–1.80) 0.044 1.35 (1.00–1.82) 0.047
Sodium >141 mmol/L     
  Chloride ≤100 mmol/L 0.88 (0.61–1.29) 0.52 0.92 (0.62–1.35) 0.66
  Chloride >100 to ≤104 mmol/L Reference  Reference  
  Chloride >104 mmol/L 0.82 (0.61–1.10) 0.18 0.85 (0.63–1.14) 0.26
Interaction sodium tertiles×chloride tertiles  0.028  0.16
Interaction sodium tertiles×chloride splines  0.019  0.039
HHF Overall     
  Chloride ≤100 mmol/L 1.28 (1.10–1.49) 0.002 1.07 (0.91–1.26) 0.39
  Chloride >100 to ≤104 mmol/L Reference  Reference  
  Chloride >104 mmol/L 1.18 (0.99–1.40) 0.063 1.17 (0.98–1.40) 0.076
Sodium ≤138 mmol/L     
  Chloride ≤100 mmol/L 1.66 (1.34–2.05) <0.0001 1.34 (1.07–1.67) 0.009
  Chloride >100 to ≤104 mmol/L Reference  Reference  
(Continued )
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The interplay between chloride and sodium is furthermore 
illustrated in a 3-dimensional contour surface graph in Figure 
I in the Data Supplement.
Prognostic Impact Assessment
The addition of chloride (as continuous cubic spline) and its 
interaction with sodium (in tertiles and continuous cubic spline) 
Figure 2. Kaplan–Meier curves for the studied outcomes of all-cause mortality (ACM), cardiovascular mortality (CVM), and hospitalization 
for heart failure (HHF) according to serum chloride tertiles within serum sodium subgroups. Chloride is expressed in mmol/L. The above 
panels represent illustrative univariable models. N indicates number.
  Chloride >104 mmol/L 1.31 (0.96–1.79) 0.093 1.37 (1.00–1.88) 0.052
Sodium >138 to ≤141 mmol/L     
  Chloride ≤100 mmol/L 1.31 (0.98–1.76) 0.072 1.07 (0.79–1.46) 0.65
  Chloride >100 to ≤104 mmol/L Reference  Reference  
  Chloride >104 mmol/L 1.13 (0.85–1.52) 0.40 1.15 (0.85–1.55) 0.38
Sodium >141 mmol/L     
  Chloride ≤100 mmol/L 0.38 (0.23–0.63) 0.0002 0.42 (0.25–0.69) 0.0006
  Chloride >100 to ≤104 mmol/L Reference  Reference  
  Chloride >104 mmol/L 0.91 (0.68–1.21) 0.51 0.91 (0.68–1.21) 0.51
Interaction sodium tertiles×chloride tertiles  <0.0001  0.001
Interaction sodium tertiles×chloride splines  0.002  0.041
Two P values for interaction are provided: one for the crude model and another for the adjusted model. ACM indicates all-cause mortality; 
CI, confidence interval; CVM, cardiovascular mortality; HHF, hospitalization for heart failure; and HR, hazard ratio.
*Adjusted for sex, age, systolic blood pressure, diabetes mellitus, atrial fibrillation, heart failure history, peripheral artery disease, hemoglobin, 
estimated glomerular filtration rate, blood urea nitrogen, left ventricular ejection fraction, Killip class, diuretic use, and body mass index.
Table 2. Continued
  Crude HR (95% CI) P Value Adjusted HR (95% CI)* P Value
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to a prognostic model (including sex, age, systolic blood pres-
sure, diabetes mellitus, atrial fibrillation, HF history, periph-
eral artery disease, hemoglobin, estimated glomerular filtration 
rate, blood urea nitrogen, left ventricular ejection fraction, Kil-
lip class, diuretic use, and body mass index) did not add prog-
nostic information to the model for any outcome using the NRI 
method (Table 3). Using IDI, the additional prognostic infor-
mation was modest and clinically irrelevant (IDI for ACM plus 
interaction with spline sodium=0.2% [0.0%–0.7%]; P=0.014; 
IDI for CVM plus interaction with spline sodium=0.2% 
[0.1%–0.8%]; P=0.004; IDI for HHF plus interaction with 
spline sodium=0.2% (−0.0 to 0.8); P=0.078; Table 3). The dis-
crimination of risk estimation as assessed by C statistics was 
also not improved by serum chloride (Table 3).
The prognostic improvement assessment was also performed 
within sodium tertiles (Table VI in the Data Supplement).
Discussion
In a large population of post-MI complicated by reduced left ven-
tricular function and HF, a significant interaction between sodium 
and chloride was observed: low serum chloride (<97 mmol/L 
as continuous variable) was associated with mortality, but not 
hospitalization for HF, in the setting of lower sodium. Overall, 
chloride and its interaction with sodium did not add clinically 
relevant prognostic information on top of other well-established 
prognostic variables nor increased the discriminative capacity of 
the model. Taken together, these data suggest that sodium and 
chloride should be considered together for outcome prediction.
Chloride Pathophysiology and Interplay With 
Sodium
Chloride is the most important anion in plasma and interstitial 
fluid, the 2 compartments that make up extracellular fluid. It 
accounts for approximately one third of plasma tonicity and 
for two thirds of all negative charges in plasma.25 Despite its 
major importance, chloride has received little attention in car-
diovascular diseases.9
Dietary sodium chloride is the main source of chloride in 
the body, and its excretion is mainly performed by the kidney, 
although >80% of filtered chloride is reabsorbed in the proxi-
mal tubule.26 In addition, gastrointestinal secretions are also 
rich in chloride, with gastric secretions being the predominant 
source.27
Hyper- and hypochloremia are frequent in hospitalized 
patients with acute and unstable conditions.25 The most fre-
quent and reversible cause of hyperchloremia is the adminis-
tration of intravenous chloride-rich fluids, such as 0.9% NaCl 
(saline) with supraphysiological chloride content.28 On the 
contrary, hypochloremia is much more frequent in associa-
tion with congestive states/neurohormonal activation, either 
by chloride loss via diuretic administration or by water gain 
(eg, congestive HF and inappropriate secretion of arginine 
vasopressin).25,29,30 Neurohormonal activation with impaired 
arginine vasopressin secretion is also important in patients 
with left ventricular dysfunction even without overt HF and 
increases when diuretics are added to the therapy because of 
volume depletion induction.31 Hence, lower chloride levels 
may be associated either with dilutional states or with electro-
lyte depletion states, especially when chloride is lower relative 
to sodium, which can occur in the setting of diuretic-induced 
salt wasting (with predominant excretion of chloride in the 
urine in exchange of bicarbonate that is retained to maintain 
electroneutrality).32
Hyponatremia is the most common electrolyte disor-
der in hospitalized patients.33 The presence of hyponatremia 
at admission or during index hospitalization is associated 
Table 3. Net Reclassification Index, Integrated Discrimination Index, and C-Index 
Using Chloride as Continuous Cubic Spline and Its Interaction With Sodium in Tertiles 
and in Continuous Cubic Spline
 
 
 
 
 
 
+Chloride in Spline+Interaction  
With Sodium in Tertiles
+Chloride in Spline+Interaction  
With Sodium in Spline
Overall Overall
Index (95% CI) P Value Index (95% CI) P Value
ACM NRI, % 5.2 (−0.7 to 9.3) 0.080 1.9 (−1.4 to 8.5) 0.10
IDI, % 0.4 (0.2 to 0.9) <0.0001 0.2 (0.0 to 0.7) 0.014
C-index 0.003 (0.000 to 0.006) 0.043 0.002 (−0.000 to 0.004) 0.11
CVM NRI, % 5.7 (−0.3 to 9.8) 0.060 3.0 (−2.6 to 8.3) 0.17
IDI, % 0.4 (0.2 to 1.0) <0.0001 0.2 (0.1 to 0.8) 0.004
C-index 0.003 (−0.000 to 0.006) 0.087 0.002 (−0.001 to 0.004) 0.18
HHF NRI, % 3.2 (−1.7 to 9.1) 0.18 6.3 (−1.2 to 10.1) 0.12
IDI, % 0.3 (0.1 to 0.7) <0.0001 0.2 (−0.0 to 0.8) 0.078
C-index 0.001 (−0.002 to 0.004) 0.43 0.001 (−0.002 to 0.004) 0.56
All models were adjusted for sex, age, systolic blood pressure, diabetes mellitus, atrial fibrillation, heart 
failure history, peripheral artery disease, hemoglobin, estimated glomerular filtration rate, blood urea nitrogen, 
left ventricular ejection fraction, Killip class, diuretic use, and body mass index. For NRI and IDI, the time point 
of event definition was the median follow-up for each end point. 
ACM indicates all-cause mortality; CI, confidence interval; CVM, cardiovascular mortality; HHF, heart failure 
hospitalization; IDI, integrated discrimination index; and NRI, net reclassification index.
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with increased rates of adverse outcomes,34 and in which, 
patients with acute MI are no exception.35 In HF and acute 
MI, hyponatremia may be dilutional or depletional29 because 
loop diuretics are frequently used in the acute HF and MI set-
tings.36,37 These agents block the sodium/potassium/chloride 
cotransporter in the thick ascending limb of Henle loop, which 
is relatively impermeable to water. This interference of loop 
diuretics with renal capacity to concentrate urine may result 
in the production of relatively hypotonic urine (≈120 mmol/L 
of urinary sodium)38 and, therefore, offer a relative protec-
tion against hyponatremia because sodium will thereafter be 
reabsorbed in the distal tubule. However, loop diuretics do not 
protect against hypochloremia because, contrary to sodium, 
chloride will not be distally reabsorbed.39,40 On the contrary, 
thiazides generate less hypotonic urine by inhibiting reab-
sorption of sodium and chloride from the distal convoluted 
tubules and, therefore, may aggravate both hyponatremia and 
hypochloremia.41,42 Hypothetically, patients with more severe 
congestion would more often display dilutional hyponatre-
mia, which, as stated above, is associated with worse prog-
nosis. These patients are also more likely to be submitted 
to higher diuretic doses (in attempts to relieve congestion), 
which, in turn, may induce (or aggravate) hypochloremia. 
This putative mechanism could provide an explanation as to 
why prognosis is worse when a patient has both lower sodium 
and low chloride. These distinctions may have clinical impli-
cations in diuretic strategies for acute HF and MI.40 In our 
study, diuretics were systematically considered as adjustment 
parameters in all multivariable analyses; however, no interac-
tion was observed between diuretic use at randomization and 
chloride regarding the studied outcomes, particularly HHF 
in which a lower serum chloride was associated with lower 
event rates only in the context of higher sodium. This finding 
could potentially translate into effective decongestion via loop 
diuretic use, which is also supported by the association of the 
lower sodium tertile (but not the higher tertile) with increased 
HHF rates (Table V and Figure I in the Data Supplement). In 
other words, patients undergoing effective decongestion may 
present lower chloride levels with normal/high sodium, which 
may provide a putative explanation for the lower HHF in this 
subgroup.
Serum Chloride as Prognostic Marker
Our findings derived from a large sample of complicated 
post-MI patients suggest that lower chloride levels at random-
ization were associated with higher ACM and CVM rates in 
the presence of low serum sodium levels (P for interaction 
<0.05). This finding is represented in Figure 1 for continu-
ous chloride (represented as restricted cubic splines adjusted 
models). When analyzing chloride and sodium categories/
subgroups (ie, tertiles), lower serum chloride was also asso-
ciated with ACM and CVM within the lower sodium tertile 
and in the midrange sodium tertile. This information captured 
in categories is not as refined as the information represented 
for continuous observations because categories capture all 
events within that subgroup, that is, very low and normal–
low electrolyte levels are treated the same way incorporating 
less accurate information. Of more significant interest, serum 
chloride (and serum sodium) and its interaction with sodium 
did not add relevant prognostic information on top of age, sex, 
systolic blood pressure, diabetes mellitus, atrial fibrillation, 
HF history, peripheral artery disease, hemoglobin, estimated 
glomerular filtration rate, urea, left ventricular ejection frac-
tion, Killip class, diuretic use, and body mass index, nor did 
it increase the discriminative capacity of this model. Intrigu-
ingly, for the outcome of first HHF, low serum chloride was 
associated with lower event rates only in the context of higher 
sodium (>141 mmol/L), although only 19 HHF events were 
observed in this subgroup, and these data may, therefore, be 
imprecise; however, this lower rate may be because of a more 
effective decongestion via loop diuretic use, as discussed 
above.
These results are complementary to those described by 
Grodin et al9 derived from 2 independent acute HF cohorts. 
In these cohorts, the prognostic value of serum chloride was 
stronger than and independent from sodium levels with regard 
to ACM (although neither CVM nor HHF were tested in 
these studies). Nonetheless, in these acute HF cohorts, there 
was also no increase in the overall C statistic of the multi-
variable model with the addition of chloride (0.68 versus 
0.69; P=0.50), whereas adding chloride to the multivariable 
model offered modest risk reclassification improvement 
(NRI=17.2%; P=0.006 and IDI=10%; P<0.001).9,43 Of note, 
these acute HF cohorts had a much smaller sample size than 
the present series, limiting the power for the assessment of 
interaction analysis, which is a statistically weak test depend-
ing on sample size and event rate.24 In this regard, our data 
supplement those assessed by Grodin et al, thus providing 
further insight into sodium/chloride interplay. Chloride is 
likely a stronger prognosticator than sodium (as also demon-
strated herein), although the interpretation of these electro-
lytes should be considered together. Such chloride/sodium 
interplay is also supported by mechanistic data in which both 
serum chloride and sodium were associated with poor diuretic 
efficiency and negatively correlated with plasma renin lev-
els, with chloride being the main independent driver of these 
associations. Moreover, chloride supplementation has been 
associated with an improvement in diuretic response.44 In the 
chronic HF setting, low serum chloride has also been associ-
ated with dismal outcome.10,11 An additional explanation for 
the differences found between these different populations is 
that HF and post-MI are distinct settings with different presen-
tations, treatments, and prognosis, despite the fact that ≈60% 
of our population had left ventricular ejection fraction <35% 
and ≈20% had HF history, without significant interaction in 
these subgroups (Table VII in the Data Supplement). In par-
ticular, fluid management plays a central role in HF therapy. 
In this regard, serum chloride is essential for osmotic pressure 
maintenance and movement of water between fluid compart-
ments.45 Moreover, despite repeated associations of serum 
sodium with morbidity and mortality in patients with HF, 
pharmacological therapies that target serum sodium levels, 
such as vasopressin antagonists, have not improved patient 
outcomes,46 suggesting a potential role of serum chloride in 
disease progression.8 In the MI context (even if complicated 
by HF), serum chloride is likely to have a less important role 
because effective reperfusion and myocardial protection are 
the cornerstone therapies in this setting.47
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Clinical and Research Implications
Despite obvious challenges, these results provide further 
insight on electrolyte management: in the setting of post-MI 
with heart failure with reduced ejection fraction, our find-
ings suggest that sodium and chloride should be interpreted 
together. Analyzing their interplay and potential causes for 
their dysregulation may help clinicians in refining their out-
come prediction and in tailoring therapeutic strategies. For 
example, patients with low chloride and low sodium are 
likely to have higher mortality rates than those with normal 
levels of these electrolytes, and therefore, prompt correc-
tion should be attempted. However, low serum chloride in 
the context of high sodium may translate in the use of loop 
diuretics and effective decongestion, which may be protective 
in the case of congestive HF. Moreover, high and very-high 
chloride levels are also likely to be associated with increased 
mortality rates (as the curves are U shaped, despite the wide 
CIs crossing the HR=1 level) even in the context of low/nor-
mal sodium.
Study Limitations
Several limitations should be acknowledged in this study. First, 
given the post hoc nature of this study, the limitations inher-
ent to retrospective analyses are, thus, applicable. Second, 
because of their absence in the database, we did not account 
for the change in chloride/sodium levels over time, which can 
potentially add predictive information to the randomization-
only measurement. In a recent analysis of acute HF patients, 
low serum chloride at hospital admission was strongly associ-
ated with impaired decongestion. Moreover, new or persistent 
hypochloremia 14 days later was also independently associ-
ated with reduced survival, whereas hypochloremia that was 
resolved by day 14 was not.12 Third, the patients herein were 
from high-risk MI trials with strict inclusion/exclusion cri-
teria that can produce a sample that may not be representa-
tive of general clinical practice, therefore also affecting the 
generalizability of our findings. Fourth, although bicarbonate/
chloride interplay has been explored in other cohorts,9 serum 
bicarbonate levels were not available in the present data set. 
Fifth, there were no available data regarding diuretic doses 
and type of diuretics used nor regarding the congestive status 
of the patients, which could provide further insight on sodium/
chloride interplay. Sixth, chloride and sodium levels were 
measured at randomization, which varied between 12 hours 
and 21 days after admission; hence, the electrolyte levels may 
not reflect actual baseline admission values. Moreover, these 
randomization values are subject to the impact of treatments 
or post-MI complications. However, these varying timings do 
not represent a systematic error but rather represent a random 
error (ie, imprecision), reinforcing the strength of the associa-
tions.48 Nonetheless, further studies are required to understand 
the underlying conditions associated with this dysregulation 
and its ensuing correction or aggravation. Seventh, the High-
Risk MI Database Initiative data set does not contain the ran-
domized study treatment, so no comparisons could be made 
between the agents investigated.13 Finally, also lacking were 
data regarding patient decisions and medication changes that 
could possibly have an impact on chloride levels and progno-
sis (such as loop diuretics dose).
Conclusions
In a large post-MI database with systolic dysfunction and 
HF in which only half of the patients were on diuretics, we 
observed a significant interaction between serum chloride 
and sodium: low serum chloride was associated with mortal-
ity (but not HHF) in the setting of lower sodium. Overall, 
chloride and its interaction with sodium did not add clini-
cally relevant prognostic information on top of other well-
established prognostic variables. Taken together, these data 
support an integrated and critical consideration of chloride 
and sodium interplay.
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CLINICAL PERSPECTIVE
In the setting of postmyocardial infarction with heart failure and reduced ejection fraction, our findings suggest that sodium 
and chloride should not be interpreted is isolation but rather should be interpreted together. Analyzing their interplay and 
potential causes for their dysregulation may help clinicians in refining their outcome prediction and in tailoring therapeutic 
strategies. For example, patients with low chloride and low sodium are likely to have higher mortality rates than those with 
normal levels of these electrolytes, and therefore prompt correction should be attempted. However, low serum chloride in the 
context of high sodium may translate in the use of loop diuretics and effective decongestion, which may be protective in the 
case of congestive heart failure. Moreover, high and very-high chloride levels are also likely to be associated with increased 
mortality rates (as the association of chloride levels and outcomes is U shaped) even in the context of low/normal sodium.
